<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997097</url>
  </required_header>
  <id_info>
    <org_study_id>7574</org_study_id>
    <nct_id>NCT03997097</nct_id>
  </id_info>
  <brief_title>Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease</brief_title>
  <acronym>VU-INHIB</acronym>
  <official_title>Phosphodiesterase-type 5 Inhibitors in Adult and Adolescent Patients With Univentricular Heart Disease: a Multi-center, Randomized, Double Blind Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5)&#xD;
      inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the&#xD;
      level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV)&#xD;
      remains limited. the investigators present the SV-INHIBITION study rationale, design and&#xD;
      methods.The SV-INHIBITION trial is a nationwide multicentre, randomised, double blind,&#xD;
      placebo-controlled, phase III study, aiming to evaluate the efficacy of sildenafil on the&#xD;
      ventilatory efficiency during exercise, in teenagers and adult patients (&gt;15 y.o.) with a SV.&#xD;
      Patients with pulmonary arterial hypertension (mean pulmonary arterial pressure (mPAP) &gt; 15&#xD;
      mmHg and trans-pulmonary gradient &gt; 5 mmHg) measured by cardiac catheterisation, will be&#xD;
      eligible. The primary outcome is the variation of the VE/VCO2 slope, measured by a&#xD;
      cardiopulmonary exercise test, between baseline and 6 months of treatment. A total of 50&#xD;
      patients are required to observe a decrease of 5 Â± 5 points in the VE/VCO2 slope, with a&#xD;
      power of 90% power and an alpha risk of 5%. The secondary outcomes are: clinical outcomes, 6&#xD;
      minute walk test, SV function, NT Pro BNP, VO2max, stroke volume, mPAP, trans-pulmonary&#xD;
      gradient, SF36 quality of life score, safety and acceptability. This study aims to answer the&#xD;
      question whether PDE5 inhibitors should be prescribed in patients with a SV. This trial has&#xD;
      been built focusing on the 3 levels of research defined by the WHO: disability (exercise&#xD;
      tolerance), deficit (SV function), and handicap (quality of life).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 Patients with a single ventricle (e.g. univentricular heart), as defined by the ACC-CHD&#xD;
      classification, with a mean pulmonary arterial pressure (mPAP) &gt; 15 mmHg and a&#xD;
      trans-pulmonary gradient (TPG) &gt; 5 mmHg, and aged 15 years old and above, will be&#xD;
      prospectively recruited in the participating centres during their regular follow-up.&#xD;
&#xD;
      Patients wil be randomised into 2 groups:&#xD;
&#xD;
        -  Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per&#xD;
           day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent&#xD;
           and adult patients, and for a period of 6 months.&#xD;
&#xD;
        -  Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6&#xD;
           months. To guarantee the double blind, capsules will be similar in size and colour and&#xD;
           will be differentiated only by a vial number regarding to the randomization list. The&#xD;
           clinical trials unit of the sponsor's pharmacy will centralize treatment allocation and&#xD;
           supply to the participating centres. Drug management (reception, storage, delivery and&#xD;
           traceability) will be ensured by the pharmacies of the participating centres.&#xD;
&#xD;
      After the 6 month-treatment period, patients will be followed for 3 months, and undergo at&#xD;
      least 2 safety visits (1 and 3 months after intervention, and if necessary, any supplementary&#xD;
      unscheduled visits). In accordance with the recommendations of the drug notice, the treatment&#xD;
      will be suspended progressively over 1 week (20 mg b.i.d for 3 days, then 20 mg q.d. for 4&#xD;
      days, and then stopped) with a reinforcement of the surveillance. Patients will be able to&#xD;
      contact an emergency number during this period and the investigator may decide to continue&#xD;
      open treatment with sildenafil if clinically justified.&#xD;
&#xD;
      The study will be conducted in compliance with the Good Clinical Practices protocol and&#xD;
      Declaration of Helsinki principles. It was approved by a drawn National Ethics Committee&#xD;
      (CPP) and by the French National Agency of Medicine and Health Products Safety (ANSM).&#xD;
      Informed consent will be obtained from all patients and their parents or legal guardians for&#xD;
      minors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventilatory efficiency M0</measure>
    <time_frame>Month 0</time_frame>
    <description>ventilatory efficiency, e.g. the VE/VCO2 slope, measured by CPET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ventilatory efficiency M6</measure>
    <time_frame>Month 6</time_frame>
    <description>ventilatory efficiency, e.g. the VE/VCO2 slope, measured by</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VO2 max M0</measure>
    <time_frame>Month 0</time_frame>
    <description>maximum oxygen uptake mesured by Cardio-pulmonary exercise test (CPET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max M6</measure>
    <time_frame>Month 6</time_frame>
    <description>maximum oxygen uptake mesured by Cardio-pulmonary exercise test (CPET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilatory anaerobic threshold M0</measure>
    <time_frame>Month 0</time_frame>
    <description>VAT using Beaver's method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilatory anaerobic threshold M6</measure>
    <time_frame>Month 6</time_frame>
    <description>VAT using Beaver's method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen pulse M0</measure>
    <time_frame>Month 0</time_frame>
    <description>ratio VO2/heart rate M0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen pulse M6</measure>
    <time_frame>Month 6</time_frame>
    <description>ratio VO2/heart rate M6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OUES M0</measure>
    <time_frame>Month 0</time_frame>
    <description>oxygen uptake efficiency slope mesured by CPET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OUES M6</measure>
    <time_frame>Month 6</time_frame>
    <description>oxygen uptake efficiency slope mesured by CPET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class M0</measure>
    <time_frame>Month 0</time_frame>
    <description>Functional class from I to IV (New York Heart Association Functional classification).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class M6</measure>
    <time_frame>Month 6</time_frame>
    <description>Functional class from I to IV (New York Heart Association Functional classification).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure M0</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function evaluation with non-invasive imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure M6</measure>
    <time_frame>Month 6</time_frame>
    <description>function evaluation with non-invasive imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation SaO2</measure>
    <time_frame>Month 0</time_frame>
    <description>oxygen saturation measured using a transcutaneous sensor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation SaO2</measure>
    <time_frame>Month 6</time_frame>
    <description>oxygen saturation measured using a transcutaneous sensor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>Month 0</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>Month 6</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Month 0</time_frame>
    <description>The SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Month 6</time_frame>
    <description>The SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic blood flow</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic blood flow</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection fraction</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection fraction</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2D strain SV function</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2D strain SV function</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic blood flows in phase contrast</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic blood flows in phase contrast</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary blood flows in phase contrast</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary blood flows in phase contrast</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection fraction</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection fraction</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection volume</measure>
    <time_frame>Month 0</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV systolic ejection volume</measure>
    <time_frame>Month 6</time_frame>
    <description>SV function evaluation with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT Pro BNP</measure>
    <time_frame>Month 0</time_frame>
    <description>blood test checked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT Pro BNP</measure>
    <time_frame>Month 6</time_frame>
    <description>blood test checked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced expiratory volume in 1 s (FEV1 )</measure>
    <time_frame>month 0</time_frame>
    <description>FEV1 spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced expiratory volume in 1 s (FEV1 )</measure>
    <time_frame>month 6</time_frame>
    <description>FEV1 spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity FVC</measure>
    <time_frame>month 0</time_frame>
    <description>FVC spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity FVC</measure>
    <time_frame>month 6</time_frame>
    <description>FVC spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1%</measure>
    <time_frame>month 0</time_frame>
    <description>FEV1/FEVC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1%</measure>
    <time_frame>month 6</time_frame>
    <description>FEV1/FEVC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEMM25/75</measure>
    <time_frame>month 0</time_frame>
    <description>DEMM25/75 measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEMM25/75</measure>
    <time_frame>month 6</time_frame>
    <description>DEMM25/75 measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capillary lung volume</measure>
    <time_frame>month 0</time_frame>
    <description>pulmonary CO/NO transfer (patient seated and lying down)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capillary lung volume</measure>
    <time_frame>month 6</time_frame>
    <description>pulmonary CO/NO transfer (patient seated and lying down)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac catheterization</measure>
    <time_frame>month 0</time_frame>
    <description>pulmonary arterial pressure mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac catheterization</measure>
    <time_frame>month 6</time_frame>
    <description>pulmonary arterial pressure mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients compliant at 6 months of study treatment</measure>
    <time_frame>month 6</time_frame>
    <description>percentage of patients compliant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>month 6</time_frame>
    <description>type of Averse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>month 6</time_frame>
    <description>type of serious Averse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Single-ventricle</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Univentricular Heart</condition>
  <arm_group>
    <arm_group_label>sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>â¢ Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>â¢ Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day</description>
    <arm_group_label>sildenafil</arm_group_label>
    <other_name>sildenafil group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Patients randomised in the group placebo in 3 oral doses of per day</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 15 years of age and over.&#xD;
&#xD;
          2. Patient's weight over 20 kg&#xD;
&#xD;
          3. Patients with CHD with a single ventricular type defined by the classification of&#xD;
             congenital heart diseases in Orphanet (53).&#xD;
&#xD;
          4. PAH defined by diagnostic catheterization with mean PAP &gt; 15 mmHg and a&#xD;
             trans-pulmonary gradient &gt; 5 mmHg, performed as part of the usual follow-up. No&#xD;
             definition of PAH in SV is available as a result of a particular physiology.&#xD;
             Therefore, we chose the 15mmHg cut-off, which is used in clinical routine to allow or&#xD;
             contra-indicate the Fontan procedure [50,51].&#xD;
&#xD;
          5. Appropriate written informed consent (adult patients, legal parents for teenagers),&#xD;
             and formal assent (teenagers), should to be provided.&#xD;
&#xD;
          6. Beneficiary of a health insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who is unable to perform a cardio-pulmonary exercise test.&#xD;
&#xD;
          2. Cardiac surgery planned during the trial.&#xD;
&#xD;
          3. Patient treated by any pulmonary arterial vasodilator drug, as defined in the 2015 PH&#xD;
             guidelines (52), within 6 months before inclusion, regardless the duration and the&#xD;
             type(s) (oral, intravenous, subcutaneous, inhaled) of administration.&#xD;
&#xD;
          4. Patient treated by Sildenafil or any other type of phosphodiesterase-type 5 inhibitor&#xD;
             (such as tadalafil) within 6 months before inclusion, regardless the duration of&#xD;
             administration.&#xD;
&#xD;
          5. Interventional cardiac catheterization planned during the trial (collateral occlusion,&#xD;
             fenestration occlusion, stenting, angioplasty, ablation of rhythm disorder), other&#xD;
             than during the screening.&#xD;
&#xD;
          6. Participation in another clinical trial or administration of an off-label drug in the&#xD;
             4 weeks preceding the screening.&#xD;
&#xD;
          7. Pregnancy, desire for pregnancy, absence of contraception during the study period.&#xD;
&#xD;
          8. Severe hepatic insufficiency (Child-Pugh C class).&#xD;
&#xD;
          9. Hypersensitivity to the active substance or to any of the excipients of the tablet:&#xD;
&#xD;
             microcrystalline cellulose, calcium hydrogen phosphate anhydrous, croscarmellose&#xD;
             sodium, stearate of magnesium, hypromellose, titanium dioxide (E171), monohydrate&#xD;
             lactose, glycerol triacetate.&#xD;
&#xD;
         10. Combination with products called &quot;nitric oxide donors&quot; (such as amyl nitrite) or with&#xD;
             nitrates in any form, due to the hypotensive effects of nitrates.&#xD;
&#xD;
         11. Concomitant administration of PDE5 inhibitors, such as Sildenafil, with guanylate&#xD;
             cyclase stimulators, such as Riociguat.&#xD;
&#xD;
         12. Combination with the most potent inhibitors of CYP3A4 (eg ketoconazole, itraconazole,&#xD;
             ritonavir).&#xD;
&#xD;
         13. Disposition to priapism, sclerosis of corpora cavernosa, disease of La Peyronie,&#xD;
             sickle cell anemia, multiple myeloma, leukemia.&#xD;
&#xD;
         14. Uncontrolled hypotension or risk of hypotension: water depletion, obstruction to&#xD;
             ejection of the left ventricle, dysfunction of the autonomic nervous system, patient&#xD;
             under alpha-blocker.&#xD;
&#xD;
         15. Severe cardiovascular events, recent (&lt;3 months) or not stabilized: myocardial&#xD;
             infarction, unstable angina, sudden cardiac death, ventricular arrhythmia,&#xD;
             cerebrovascular hemorrhage.&#xD;
&#xD;
         16. Active hemorrhagic disorders.&#xD;
&#xD;
         17. Active gastro-duodenal ulcer.&#xD;
&#xD;
         18. Patients with loss of vision of an eye due to non-arteritic anterior ischemic optic&#xD;
             neuropathy (NAION), whether or not this event has been associated with previous&#xD;
             exposure to a PDE5 inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal AMEDRO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal AMEDRO, MD, PhD</last_name>
    <phone>00 33 4 67 33 66 32</phone>
    <email>p-amedro@chu-montpellier.fr</email>
  </overall_contact>
  <link>
    <url>http://dx.doi.org/10.1002/ehf2.12630</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Amedro P, Gavotto A, Abassi H, Picot MC, Matecki S, Malekzadeh-Milani S, Levy M, Ladouceur M, Ovaert C, Aldebert P, Thambo JB, Fraisse A, Humbert M, Cohen S, Baruteau AE, Karsenty C, Bonnet D, Hascoet S; SV-INHIBITION study investigators. Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design. ESC Heart Fail. 2020 Apr;7(2):747-756. doi: 10.1002/ehf2.12630. Epub 2020 Mar 9.</citation>
    <PMID>32147955</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital heart defect</keyword>
  <keyword>single ventricle</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>sildenafil</keyword>
  <keyword>pulmonary vasodilator</keyword>
  <keyword>Eexercise capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Univentricular Heart</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

